Document is current

Article History

Received: 19 September 2019

Accepted: 28 April 2020

First Online: 8 July 2020

Competing interests

: Joyce O’Shaughnessy: <i>Financial</i>: Honoraria from Seattle Genetics. Speaking fees from Blue Earth Diagnostics, and Novartis. Vendor-sponsored travel from AstraZeneca, Blue Earth Diagnostics, Eli-Lilly, Merck, Novartis, and Seattle Genetics. Consultant/advisory role for AstraZeneca, Celgene, Eli-Lilly, LaRoche, Lilly USA, Merck, Novartis, and Pfizer. <i>Nonfinancial</i>: Nothing to disclose. Javier Cortes: <i>Financial</i>: Consulting/Advisor for Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, and Merck Sharp & Dohme. Honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung, Lilly, and Merck Sharp & Dohme. Research funding (to the Institution) from Roche, Ariad Pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffman-La Roche, Guardant Health, Merck Sharp & Dohme, Pfizer, Piqur Therapeutics, Puma C, Queen Mary University of London, and Seagen. Stock, patents, and intellectual property with MedSIR. <i>Nonfinancial:</i> Nothing to disclose. Chris Twelves: <i>Financial:</i> Personal fees and costs of clinical trials from Eisai during the conduct of the study. Personal fees and costs related to attending academic meetings from Pfizer; personal fees and costs related to clinical trials from Nektar; costs related to attending academic meetings from Roche/Genentech; and costs related to meeting attendance from Amcure, all outside the submitted work. <i>Nonfinancial:</i> Eisai. Lori J. Goldstein: <i>Financial</i>: Consultant/advisor for Merck, Genentech, Syndax, Immunomedics, Aduro, Genomic Health, Amgen, and Mylan; research support for Merck and Genentech; CME lecture for Genomic Health and Teva; DSMB for Daiichi Sankyo. <i>Nonfinancial:</i> Patient education for the Komen Foundation. Karenza Alexis: <i>Financial</i>: Former employee of Eisai Inc. <i>Nonfinancial:</i> Nothing to disclose. Ran Xie: <i>Financial</i>: Current employee of Eisai Inc. <i>Nonfinancial:</i> Nothing to disclose. Carlos Barrios: <i>Financial</i>: Clinical research support from AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Celgene, Covance, Lilly, Medivation, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, PharmaMar, and Roche/Genentech. Advisory board and consulting fees from Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche/Genentech, and Eisai. <i>Nonfinancial:</i> Nothing to disclose. Takayuki Ueno: <i>Financial</i>: Personal fees from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., AstraZeneca K.K., Taiho Pharmaceutical Co., Ltd., and Novartis Pharma K.K., outside the submitted work. <i>Nonfinancial</i>: Nothing to declare.